

- Mercury exposure/poisoning (*Cont.*):
 reference range for, 2766t
 skin manifestations of, 240t, 382
 treatment of, 472e-3t
- Merkel cell carcinoma, 502, 926, 928
- Merogony, 1369
- Meropenem
 for *Acinetobacter* infections, 1037t
 for anaerobic bacterial infections, 1101, 1101t
 for *B. cepacia* infection, 1045t
 for community-acquired pneumonia, 767t, 808t
 for febrile neutropenia, 491
 for glanders, 1045t
 for health care-associated pneumonia, 812t
 indications for, 940t, 941
 for intraabdominal infections, 767t
 for melioidosis, 1045t
 for meningitis, 887t, 889, 889t
 for multidrug-resistant TB, 205e-7
 for osteomyelitis, 841t
 for *P. aeruginosa* infections, 808t, 1045t
 in pregnancy and lactation, 937t
 resistance to, 933, 940t
 for sepsis/septic shock, 767t, 1757t
 for Whipple's disease, 1093-1094
- Merosin deficiency, 462e-9, 462e-10t
- Merozoites, *Plasmodium*, 1369
- MERRF (myoclonic epilepsy with ragged red fibers) syndrome
 clinical features of, 85e-5, 85e-6t, 451e-3t, 462e-16
 diagnosis of, 85e-7, 462e-16
 mitochondrial DNA mutation in, 85e-5, 85e-6t, 85e-7, 451e-3t, 462e-16
- MERS (Middle East respiratory syndrome), 261e-9, 1204-1205
- Mesalamine, 1959-1960, 1959t
- Mesangial cells, 332e-1
- Mesangioproliferative glomerulonephritis, 1835t, 1841
- Mesenchymal stem cells, 90e-2, 453t
- Mesenchymal tumor, 609t
- Mesenteric ischemia/vascular insufficiency. *See* Intestinal ischemia
- Mesenteric lymphadenitis, 106t
- Mesenteric venous thrombosis, 1979, 1980t
- Mesial temporal lobe epilepsy, 2544, 2546f, 2546t
- MESNA, 103e-8, 139e-3, 623, 1798
- Mesoamerican nephropathy, 1855-1856
- Mesocardia, 1528
- Mesothelin, 120e-2t
- Mesothelioma
 asbestos-related, 1689
 AV conduction block in, 289e-2, 1471t
 carcinoma of unknown primary and, 120e-2t, 120e-4
 clinical features of, 1577
 immunohistochemistry of, 508
 intramyocardial, 289e-2
 pericardial effusion in, 1577
 pleural effusion in, 1717
- Meta-analysis, 26
- Metabisulfite, as asthma trigger, 1671
- Metabolic acidosis, 317
 acid-base nomogram, 316f
 in acute kidney injury, 1808, 1810
 alcoholic ketoacidosis, 299, 318-319
 in chronic kidney disease, 1814
 clinical features of, 317
 compensatory responses in, 316t
 diabetic ketoacidosis. *See* Diabetic ketoacidosis (DKA)
 drug- or toxin-induced, 64e-2, 64e-9, 319-330. *See also* Ethylene glycol poisoning; Methanol poisoning
 high-anion gap, 64e-9, 318, 318t
 hyperkalemia in, 64e-2-3, 309, 311
 lactic acid. *See* Lactic acidosis
 in mixed acid-base disorders, 316-317, 316t
 non-anion gap, 64e-6, 320-321, 320t
 in overdose/poisoning, 473e-3
 with parenteral nutrition, 98e-7
 treatment of, 317-318
- Metabolic alkalosis, 321
 acid-base nomogram, 316f
 clinical features of, 321-322
 compensatory responses in, 316t
 differential diagnosis of, 321
 etiology of, 321-322, 321t
 hypokalemia in, 64e-8, 307
 mixed acid-base disorders, 316t
 in mixed acid-base disorders, 317
 pathogenesis of, 321
 treatment of, 322
- Metabolic disease. *See also specific diseases*
 classification of, 436e-1
 clinical features of, 436e-1, 436e-1-8f
 coma due to, 1772-1773
 etiology of, 436e-1
 myopathy in, 462e-19
- Metabolic encephalopathy, 178, 1782
- Metabolic equivalent tasks (METs), 1585t, 1587, 1587t
- Metabolic rate. *See* Resting (basal) metabolic rate
- Metabolic syndrome, 2449
 adiponectin in, 2452
 age and, 2449
 cardiovascular disease and, 1439, 2450, 2452
 clinical features of, 291e-6, 2452
 diabetes mellitus and, 2405, 2449, 2452, 2454
 diagnosis of, 2450t, 2452
 epidemiology of, 2449, 2450f
 HCV infection and, 2041
 in HIV infection, 1259
 hypertension in, 291e-6, 1617, 2451-2452, 2454
 hyperuricemia/uric acid stones in, 431e-4, 2452
 insulin resistance in, 2450, 2454
 lipodystrophy and, 2450
 lipoprotein disorders in, 2451, 2453-2454
 nonalcoholic fatty liver disease and, 2452
 obesity/overweight and, 2449
 obstructive sleep apnea and, 2452
 pathophysiology of, 292e-1v, 2450-2452, 2451f
 in polycystic ovarian syndrome, 337, 2452
 prevalence of, 2254t
 proinflammatory cytokines in, 2452
 in psoriasis, 348
 risk factors for, 2449-2450
 screening/testing for, 2254t
 thrombosis risk in, 744
 treatment of, 291e-7, 2452-2454
 waist circumference in, 2450t, 2451
- Metabolomics, 6, 436e-1
- Metaboreceptors, 47e-1
- Metachromatic leukodystrophy (MLD), 91e-2-3, 432e-4t, 2608
- Metagenome, 86e-11
- Metagenomics. *See also* Human microbiome
 definition of, 6, 86e-1t, 86e-2, 769t
 impact on clinical medicine, 86e-2
 in infectious disease diagnosis, 769t
 in pathogen discovery, 772-773, 773f
- Metagonimus yokogawai*, 245e-2t. *See also* Intestinal flukes
- Metal fume fever, 1692
- Metamorphopsia, 205, 206
- Metamyelocytes, 414f, 415
- Metanephrines, 2330t
- Metapneumovirus infections. *See* Human metapneumovirus (HMPV) infections
- Metastasis-suppressor genes, 102e-10
- Metastatic calcification, 426e-7, 426e-7t
- Metastatic disease, 102e-10
 in bladder cancer, 577
 to bone, 102e-10-11, 119e-4
 bone marrow examination in, 81e-7f
 to brain. *See* Brain tumors, metastatic characteristics of, 102e-1t, 102e-10-11, 102e-11f
 in colorectal cancer, 542
 to eye, 206, 207
 gene therapy for, 91e-4
 to heart, 270e-24, 271e-8f, 271e-8v, 289e-2
 to liver, 542, 553
 to lung, 246
 in lung cancer, 511, 511t
 lymphadenopathy in, 408
 to pericardium, 1788
 in renal cell carcinoma, 579
 to skin, 76e-6f, 355, 359, 364t, 367, 501f
 to spine, 117, 605, 606, 606f
 splenomegaly in, 411
 surgery for, 103e-3
- Metastatic potential, 102e-10, 102e-11f
- Metaxalone, 473e-10t
- Metformin
 action of, 102e-13, 2413, 2414t
 adverse effects of, 644t, 1461, 1821, 2413, 2414t
 contraindications to, 2414t
 in elderly, 82
 for lifespan enhancement, 94e-7
 for metabolic syndrome, 2454
 for NALFD, 2057
 for prediabetes, 2406
 structure of, 94e-6f
 tumor-related effects of, 102e-13
 for type 2 diabetes mellitus, 2413, 2414t, 2416-2417, 2416f
- MET* gene mutations
 cancers associated with, 101e-2t
 in hereditary papillary renal carcinoma, 101e-5, 101e-6t
 in lung cancer, 507t
 in thyroid cancer, 2305t
- Methadone
 adverse effects of, 1467t
 in opioid use disorders, 468e-2, 468e-3
 for pain, 61, 91t, 94
 therapeutic monitoring of, 2765t
- Methamphetamine
 actions of, 465e-5t, 469e-3
 intracerebral hemorrhage due to, 2568, 2584
 overdose/poisoning with, 469e-3, 473e-6, 2765t
- Methane, 151e-2t, 151e-3f
- Methanogens, 86e-4
- Methanol poisoning
 acidosis in, 319
 clinical features of, 473e-12t
 laboratory evaluation of, 2765t
 mechanism of, 473e-12t
 optic neuropathy in, 203
 treatment of, 64e-9, 319, 473e-12t
- Methaqualone, 473e-11t
- Methemoglobin, 249, 636, 637, 2761t
- Methemoglobinemia, 636
- Methemoglobin inducers, 473e-11t
- Methicillin, 727t, 807, 961
- Methicillin-resistant *Staphylococcus aureus* (MRSA) infections
 in atopic dermatitis, 345
 in burn wounds, 166e-3
 cellulitis, 830
 community-acquired, 805, 807, 808t, 955, 956, 958
 control of, 918
 diagnosis of, 150e-8, 774
 emergence of, 918
 endocarditis, 822t, 823
 genomics of, 769t, 774, 776, 807
 health care-associated, 803t, 918
 meningitis. *See* Meningitis osteomyelitis, 840t
 prevalence of, 961
 risk factors for, 805
 sinusitis, 226
 treatment of, 345, 808t, 832t, 961-963, 962t
- Methimazole
 adverse effects of, 2296, 2348
 for Graves' disease, 2296
 for hyperthyroidism in pregnancy, 48
 for radioactive iodine exposure, 263e-7
 for thyroid storm, 2297
- Methionine aminopeptidase, 246e-9
- Methionine metabolism disorders, 434e-2t, 434e-3t
- Methionine synthase, 642f, 643